Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 3/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909295 | 0.91 | PLG (0.54) | HTR5APLGPLAUPYGLLMNA | |
| SCHEMBL9909286 | 0.90 | HTR5A (0.53) | HTR5ACCNT1CDK9SCN9ASCN5A | |
| SCHEMBL9909200 | 0.89 | PLAU (0.51) | HTR5APLGPLAUSCN9APYGL | |
| SCHEMBL9909195 | 0.89 | HTR5A (0.51) | HTR5ACCNT1CDK9SCN9ASCN5A | |
| SCHEMBL9907688 | 0.86 | HTR5A (0.60) | HTR5APLGPLAUPYGLMAPK1 | |
| SCHEMBL9909258 | 0.86 | HTR5A (0.76) | HTR5APLGPLAU | |
| SCHEMBL9907678 | 0.85 | HTR5A (0.57) | HTR5APLGPLAUMAPK1 | |
| SCHEMBL9907733 | 0.85 | HTR5A (0.72) | HTR5APLAU | |
| SCHEMBL9909283 | 0.84 | PLAU (0.49) | HTR5APLGPLAUSCN9ALRRK2 | |
| SCHEMBL9908017 | 0.83 | HTR5A (0.54) | HTR5APLGPLAUMAPK1KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885PLG 3328/4885PLAU 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.